Unknown

Dataset Information

0

Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice.


ABSTRACT: Following curative immunotherapy of B16F10 tumors, ~60% of mice develop a strong antibody response against cell-surface tumor antigens. Their antisera confer prophylactic protection against intravenous challenge with B16F10 cells, and also cross-react with syngeneic and allogeneic tumor cell lines MC38, EL.4, 4T1, and CT26. We identified the envelope glycoprotein (env) of a murine endogenous retrovirus (ERV) as the antigen accounting for the majority of this humoral response. A systemically administered anti-env monoclonal antibody cloned from such a response protects against tumor challenge, and prophylactic vaccination against the env protein protects a majority of naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells. These results suggest the potential for effective prophylactic vaccination against analogous HERV-K env expressed in numerous human cancers.

SUBMITTER: Kang BH 

PROVIDER: S-EPMC8049297 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5755978 | biostudies-literature
| S-EPMC7458611 | biostudies-literature
| S-EPMC7092836 | biostudies-literature
| S-EPMC5242373 | biostudies-literature
| S-EPMC5640850 | biostudies-literature
| S-EPMC1082723 | biostudies-literature
| S-EPMC6205406 | biostudies-literature
| S-EPMC4038850 | biostudies-literature
| S-EPMC6134781 | biostudies-literature
| S-EPMC7770760 | biostudies-literature